This work challenges the long‐standing axon‐centric paradigm driving functional decline in CMT1A and HNPP and identifies junctional complexes as potential actionable molecular targets for therapeutic intervention. The gene discussed is PMP22; the disease is hereditary neuropathy with liability to pressure palsies.